CEACAM5 and familial pancreatic carcinoma: For example, in pancreatic cancer, a combination assay of serum CEA, CA 19–9 and CA 242 is known to have improved the specificity and sensitivity of diagnosis and prognosis of pancreatic cancer patients [15].